Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Use of Robot in Prostatectomy to Be Approved as Senshin-iryo
September 27, 2010
- Toyobo to Strengthen Bulk Manufacturing & Contract R&D for Biopharmaceuticals
September 27, 2010
- 29 Ex-Korosho Officials Employed by 15 Drug Firms
September 27, 2010
- Mochida Applies for Escitalopram in Japan
September 27, 2010
- LabCorp to Acquire Genzyme Genetics for US$925 Mil. in Cash
September 27, 2010
- Fingolimod Approved in Russia: Novartis
September 27, 2010
- E Keppra to Expand Market for Anti-epileptic Agents: Otsuka, UCB
September 27, 2010
- 5-Aminolevulinic Acid HCl Designated as Orphan Drug
September 27, 2010
- JCR Completes Manufacturing Facility for EPO Biosimilar
September 27, 2010
- Symposiasts Call for Unification of Clinical Research, Trials
September 27, 2010
- Novartis to Keep Weighted Average Invoice Price Unchanged: Mr Mitani
September 27, 2010
- Two GM Mice Lost at Kyowa Kirin's Research Center
September 27, 2010
- Tadaharu Goto Appointed New JPMA Director General
September 27, 2010
- Eisai to Apply for Eszopiclone within FY2010
September 27, 2010
- Mediceo Encourages Its MSs to Take Exam for MR Certification
September 27, 2010
- Agensys Begins PI for AGS-16M8F for RCC
September 27, 2010
- Emerging Countries Drive Global Drug Industry: Ms Chui of IMS
September 27, 2010
- Abstract of PII for CBP501 Presented at IMIG2010: CanBas
September 27, 2010
- Prof. Morishita Calls For Creation of Environment Friendly to Bioventures
September 27, 2010
- 30% Market Share for Generics Unlikely to Be Achieved: Mr Mitsuhara
September 27, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…